DOCSLIB.ORG

In Vitro Pharmacological Characterization of RXFP3 Allosterism: an Example of Probe Dependency

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
In Vitro Pharmacological Characterization of RXFP3 Allosterism: an Example of Probe Dependency In Vitro Pharmacological Characterization of RXFP3 Allosterism: An Example of Probe Dependency Lily Alvarez-Jaimes, Steven W. Sutton*, Diane Nepomuceno, S. Timothy Motley, Miroslav Cik, Emily Stocking, James Shoblock, Pascal Bonaventure Janssen Pharmaceutical Companies of Johnson & Johnson, San Diego, California, United States of America Abstract Recent findings suggest that the relaxin-3 neural network may represent a new ascending arousal pathway able to modulate a range of neural circuits including those affecting circadian rhythm and sleep/wake states, spatial and emotional memory, motivation and reward, the response to stress, and feeding and metabolism. Therefore, the relaxin-3 receptor (RXFP3) is a potential therapeutic target for the treatment of various CNS diseases. Here we describe a novel selective RXFP3 receptor positive allosteric modulator (PAM), 3-[3,5-Bis(trifluoromethyl)phenyl]-1-(3,4-dichlorobenzyl)-1-[2-(5-methoxy-1H- indol-3-yl)ethyl]urea (135PAM1). Calcium mobilization and cAMP accumulation assays in cell lines expressing the cloned human RXFP3 receptor show the compound does not directly activate RXFP3 receptor but increases functional responses to amidated relaxin-3 or R3/I5, a chimera of the INSL5 A chain and the Relaxin-3 B chain. 135PAM1 increases calcium mobilization in the presence of relaxin-3NH2 and R3/I5NH2 with pEC50 values of 6.54 (6.46 to 6.64) and 6.07 (5.94 to 6.20), respectively. In the cAMP accumulation assay, 135PAM1 inhibits the CRE response to forskolin with a pIC50 of 6.12 (5.98 to 6.27) in the presence of a probe (10 nM) concentration of relaxin-3NH2. 135PAM1 does not compete for binding with the orthosteric radioligand, [125I] R3I5 (amide), in membranes prepared from cells expressing the cloned human RXFP3 receptor. 135PAM1 is selective for RXFP3 over RXFP4, which also responds to relaxin-3. However, when using the free acid (native) form of relaxin-3 or R3/I5, 135PAM1 doesn’t activate RXFP3 indicating that the compound’s effect is probe dependent. Thus one can exchange the entire A-chain of the probe peptide while retaining PAM activity, but the state of the probe’s c- terminus is crucial to allosteric activity of the PAM. These data demonstrate the existence of an allosteric site for modulation of this GPCR as well as the subtlety of changes in probe molecules that can affect allosteric modulation of RXFP3. Citation: Alvarez-Jaimes L, Sutton SW, Nepomuceno D, Motley ST, Cik M, et al. (2012) In Vitro Pharmacological Characterization of RXFP3 Allosterism: An Example of Probe Dependency. PLoS ONE 7(2): e30792. doi:10.1371/journal.pone.0030792 Editor: Karl-Wilhelm Koch, University of Oldenburg, Germany Received October 11, 2011; Accepted December 29, 2011; Published February 7, 2012 Copyright: ß 2012 Alvarez-Jaimes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: There are no current external funding sources for this study. Competing Interests: The authors have read the journal’s policy and have the following conflicts: Johnson & Johnson Pharmaceutical Research and Development funded this study. Authors are employees of Johnson & Johnson Pharmaceutical Research & Development, LLC or were employees of that firm at the time the research was performed. Studies described here were performed with materials described in Patents/Applications US 7893197 and US 2005074814. This does not alter the authors9 adherence to all the PLoS ONE policies on sharing data and materials. * E-mail: [email protected] Introduction RXFP1 [10] and has important roles in collagen remodeling, impacting diverse physiological processes from pregnancy [11] to RXFP3, also known as GPCR 135 [1] or the SALPR [2], is the asthma [12] and heart failure [13]. Relaxin-3 is highly and focally cognate receptor for relaxin-3 (Relaxin-3). Relaxin-3 and related expressed in the nucleus incertus of the hind brain of the mouse receptors will be referred to by their IUPHAR terminology [3]. [6,14], rat [1], and an equivalent area of the macaque [5]. Apart RXFP3 is a class A, Gi/o linked GPCR with an extensive from the Relaxin-3 distribution, behavioral data suggest that distribution in the central nervous system (CNS), particularly in Relaxin-3 has a role in stress/anxiety [15], cognition [16] and areas involved in memory, sensory and emotional processing [4]. appetite regulation [17,18]. The tissue distribution and function of The CNS distribution of RXFP3 is conserved in mice and Relaxin-3 and RXFP3 indicate potential therapeutic application macaques [5,6]. RXFP4, the INSL5 receptor, is the closest of RXFP3 modulators to treat stress/anxiety, cognitive disorders homolog to RXFP3 [7]. and metabolic diseases [19]. In vivo agonist stimulation of RXFP3 Relaxin-3 is a member of the insulin superfamily, which in rodents increases hippocampal theta emissions and improves includes insulin, insulin-like growth factor, the relaxin hormone performance in behavioral cognitive assays [16,20]. (H1/H2 Relaxin) and insulin-like peptides (INSL-3, 4, 5 and 6). In Selective orthosteric, high affinity agonist (R3/I5) and antago- addition to RXFP3, relaxin-3 is capable of high affinity interaction nist (R3(D23–27)R/I5) peptides have been discovered for RXFP3 with RXFP4. However, RXFP4 and its native ligand (INSL5) are [21,22]. The selective agonist (R3/I5) pairs the INSL-5 A chain thought to be more active in the periphery [7]. RXFP4 is a with Relaxin-3’s B chain, yielding a selective, high affinity, full pseudogene in the rat [8] and does not appear to be expressed in RXFP3/4 agonist. Residues 23 through 27 of the Relaxin-3 B the mouse brain [9]. While Relaxin-3 shares part of its name with chain are necessary for agonist activity and removing those resides H1/H2 Relaxin, it has a distinct distribution and roles compared from R3/I5 creates a competitive antagonist (R3(D23–27)R/I5). to the hormonal H1/H2 Relaxin. H1/H2 Relaxin acts through While these peptide modulators of RXFP3/4 have been useful, PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30792 Positive Allosteric Modulator of RXFP3 they must be administered i.c.v. Small molecule drugs for these was synthesized and prepared at Johnson & Johnson Pharma- receptors have yet to be described in the literature. ceutical Research and Development, L.L.C. GPCR agonists and antagonists can act either orthosterically, at the same site as the native agonist, or allosterically at a separate Cell Lines site on the receptor. Positive allosteric activity can take the form of Stable cell lines expressing RXFP3 and RXFP4 were created as allosteric agonism (activity in the absence of an orthosteric agonist) previously described [1,8,29]. Clonal, stable cell lines were made or positive allosteric modulation (PAM; requires presence of an using the receptor genes of interest, cloned into pCIneo (Promega, orthosteric agonist) [23,24,25]. Positive allosteric modulators have Madison, WI). For functional assays measuring inhibition of the several theoretical advantages over direct agonists as therapeutic cAMP pathway, the receptor constructs were transfected into SK- agents. As PAM compounds modify the efficacy of an orthosteric N-MC cells (ATCC, Manassas, VA) expressing a CRE reporter agonist and lack activity on their own, these compounds are linked to b-galactosidase expression. Other assays were performed expected to have an effect only in tissues where and when the using stable clones of HEK-293 cells (ATCC, Manassas, VA) endogenous agonist is released. The ability of PAM compounds to coexpressing the receptor gene of interest (RXFP3 or RXFP4) and exhibit biological activity in a regulated manner enhances their chimeric Ga protein GqI5 [30]. safety profile and makes them attractive tools over traditional therapeutic agents [26]. Ca2+ Mobilization Assay In the case of positive allosteric modulation, the allosteric Intracellular Ca2+assays were used to assess the effect of activity is measured in the presence of an orthosteric agonist, 135PAM1 to either increase the response to a probe quantity of referred to as a probe. Examples of PAM compounds with probe- an agonist (,EC20) or to measure changes in an agonist’s EC50 at specific activities have been described in the literature [27]. Here various compound doses. In either case, adherent HEK-293 cells we describe a RXFP3 PAM compound (135PAM1, Figure 1) expressing GqI5 were grown to confluency in DMEM media which is a striking example of probe selectivity. In this case, one supplemented with 10% fetal bovine serum, 50 iu/ml penicillin, can exchange the entire A-chain of the probe peptide while 50 mg/ml streptomycin, 1 mM Na Pyruvate, 10 mM HEPES, and retaining PAM activity, but the state of the probe’s c-terminus is 600 mg/ml G418. On the day before the assay the cells were crucial to allosteric activity of the PAM. detached with 10 mM trypsin/EDTA and seeded on black poly- D-lysine-coated 96-well plates (BD Bioscience, San Jose, CA) at a Materials and Methods density of 35,000 cells/well, then incubated overnight at 37uC, 5% CO2. On the next day, the culture medium was discarded and Materials replaced with a calcium dye solution, containing 4 mM Fluo-3 All cell culture supplies, Fluo-3 AM calcium dye and Pluronic (AM), 2.5 mM probenecid and 0.04% Pluronic acid F-127 in acid F-127 were obtained from Invitrogen (Carlsbad, CA). DM:F12 medium. Cells were incubated in the dye solution for Probenecid and forskolin were obtained from Sigma (St. Louis, 60 min at room temperature or 30 min at 37uC. Ligand- MO). Chlorophenol red-b-D-galactopyranoside (CPRG) was stimulated Ca2+ mobilization was monitored using FLIPR Tetra purchased from Roche Applied Science (Indianapolis, IN).
Load more

Recommended publications
  • The Roles Played by Highly Truncated Splice Variants of G Protein-Coupled Receptors Helen Wise
    Wise Journal of Molecular Signaling 2012, 7:13 http://www.jmolecularsignaling.com/content/7/1/13 REVIEW Open Access The roles played by highly truncated splice variants of G protein-coupled receptors Helen Wise Abstract Alternative splicing of G protein-coupled receptor (GPCR) genes greatly increases the total number of receptor isoforms which may be expressed in a cell-dependent and time-dependent manner. This increased diversity of cell signaling options caused by the generation of splice variants is further enhanced by receptor dimerization. When alternative splicing generates highly truncated GPCRs with less than seven transmembrane (TM) domains, the predominant effect in vitro is that of a dominant-negative mutation associated with the retention of the wild-type receptor in the endoplasmic reticulum (ER). For constitutively active (agonist-independent) GPCRs, their attenuated expression on the cell surface, and consequent decreased basal activity due to the dominant-negative effect of truncated splice variants, has pathological consequences. Truncated splice variants may conversely offer protection from disease when expression of co-receptors for binding of infectious agents to cells is attenuated due to ER retention of the wild-type co-receptor. In this review, we will see that GPCRs retained in the ER can still be functionally active but also that highly truncated GPCRs may also be functionally active. Although rare, some truncated splice variants still bind ligand and activate cell signaling responses. More importantly, by forming heterodimers with full-length GPCRs, some truncated splice variants also provide opportunities to generate receptor complexes with unique pharmacological properties. So, instead of assuming that highly truncated GPCRs are associated with faulty transcription processes, it is time to reassess their potential benefit to the host organism.
    [Show full text]
  • Review Genetic Dissection of Mammalian Fertility Pathways Martin M
    fertility supplement review Genetic dissection of mammalian fertility pathways Martin M. Matzuk*†‡# and Dolores J. Lamb†§ Departments of *Pathology, †Molecular and Cellular Biology and ‡Molecular and Human Genetics, and §Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA #e-mail: [email protected] The world’s population is increasing at an alarming rate and is projected to reach nine billion by 2050. Despite this, 15% of couples world-wide remain childless because of infertility. Few genetic causes of infertility have been identified in humans; nevertheless, genetic aetiologies are thought to underlie many cases of idiopathic infertility. Mouse models with reproductive defects as a major phenotype are being rapidly created and discovered and now total over 200. These models are helping to define mechanisms of reproductive function, as well as identify potential new contracep- tive targets and genes involved in the pathophysiology of reproductive disorders. With this new information, men and women will continue to be confronted with difficult decisions on whether or not to use state-of-the-art technology and hormonal treatments to propagate their germline, despite the risks of transmitting mutant genes to their offspring. espite advances in assisted reproductive have been produced by spontaneous muta- Where it all begins technologies, infertility is a major health tions, fortuitous transgene integration, Reproductive development and physiology problem worldwide. Approximately 15% of retroviral infection of embryonic stem are evolutionarily conserved processes couples are unable to conceive within one cells, ethylnitrosurea (ENU) mutagenesis across eutherian mammalian species and year of unprotected intercourse. The fertil- and gene targeting technologies3,7,8.
    [Show full text]
  • The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: a Systematized Review
    International Journal of Molecular Sciences Review The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review Hadrien Golay 1 , Simona Jurkovic Mlakar 1, Vid Mlakar 1, Tiago Nava 1,2 and Marc Ansari 1,2,* 1 Platform of Pediatric Onco-Hematology research (CANSEARCH Laboratory), Department of Pediatrics, Gynecology, and Obstetrics, University of Geneva, Bâtiment La Tulipe, Avenue de la Roseraie 64, 1205 Geneva, Switzerland 2 Department of Women-Children-Adolescents, Division of General Pediatrics, Pediatric Onco-Hematology Unit, Geneva University Hospitals (HUG), Avenue de la Roseraie 64, 1205 Geneva, Switzerland * Correspondence: [email protected] Received: 14 June 2019; Accepted: 7 August 2019; Published: 9 August 2019 Abstract: Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for several malignant and non-malignant diseases at the cost of serious treatment-related toxicities (TRTs). Recent research on extending the benefits of HSCT to more patients and indications has focused on limiting TRTs and improving immunological effects following proper mobilization and engraftment. Increasing numbers of studies report associations between HSCT outcomes and the expression or the manipulation of G protein-coupled receptors (GPCRs). This large family of cell surface receptors is involved in various human diseases. With ever-better knowledge of their crystal structures and signaling dynamics, GPCRs are already the targets for one third of the current therapeutic arsenal. The present paper assesses the current status of animal and human research on GPCRs in the context of selected HSCT outcomes via a systematized survey and analysis of the literature.
    [Show full text]
  • Relaxin Receptor RXFP1 and RXFP2 Expression in Ligament, Tendon, and Shoulder Joint Capsule of Rats
    ORIGINAL ARTICLE Rehabilitation & Sports Medicine http://dx.doi.org/10.3346/jkms.2016.31.6.983 • J Korean Med Sci 2016; 31: 983-988 Relaxin Receptor RXFP1 and RXFP2 Expression in Ligament, Tendon, and Shoulder Joint Capsule of Rats Jae Hyung Kim,1,2 Sang Kwang Lee,3 Numerous musculoskeletal disorders are caused by thickened ligament, tendon stiffness, or Seong Kyu Lee,4 Joo Heon Kim,5 fibrosis of joint capsule. Relaxin, a peptide hormone, can exert collagenolytic effect on and Michael Fredericson1 ligamentous and fibrotic tissues. We hypothesized that local injection of relaxin could be used to treat entrapment neuropathy and adhesive capsulitis. Because hormonal effect 1Division of Physical Medicine and Rehabilitation, Department of Orthopaedic Surgery, Stanford depends on the receptor of the hormone on the target cell, it is important to confirm the University, Stanford, CA, USA; 2Department of presence of such hormonal receptor at the target tissue before the hormone therapy is Physical Medicine & Rehabilitation, Eulji University initiated. The aim of this study was to determine whether there were relaxin receptors in Hospital and Eulji University School of Medicine, the ligament, tendon, and joint capsular tissues of rats and to identify the distribution of Daejeon, Korea; 3Eulji Medi-Bio Research Institute, Daejeon, Korea; 4Department of Biochemistry, Eulji relaxin receptors in these tissues. Transverse carpal ligaments (TCLs), inguinal ligaments, University School of Medicine, Daejeon, Korea; anterior cruciate ligaments (ACLs), Archilles tendons, and shoulder joint capsules were 5Department of Pathology, Eulji University School of obtained from male Wistar rats. Western blot analysis was used to identify relaxin receptor Medicine, Daejeon, Korea isoforms RXFP1 and RXFP2.
    [Show full text]
  • The Role of the Relaxin Receptor RXFP1 in Brain Cancer
    The role of the relaxin receptor RXFP1 in brain cancer By Usakorn Kunanuvat A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment for the requirements of the degree of MASTER OF SCIENCE Department of Human Anatomy and Cell Science University of Manitoba Winnipeg Copyright © 2012 by Usakorn Kunanuvat ABSTRACT Relaxin (RLN2) promotes cell migration/invasion, cell growth, and neoangiogenesis through binding to the relaxin receptor RXFP1 in many types of cancers. However, there have been no studies to determine the role of this system in brain tumors, especially in Glioblastoma Multiforme (GB), the most lethal primary brain tumor in adults. GB is a systemic brain disease and aggressively invades brain tissue. In this study, we have identified RXFP1 receptor, but not RLN2, in GB cell lines and primary GB cells from patients. RLN2 treatment resulted in a significant increase in migration of GB cell line and primary GB cells. To determine molecular mechanisms that facilitate RXFP1-mediated migration in GB cells, we employed a pseudopodia assay and 2D LC-MS/MS to investigate the protein composition at cell protrusions (pseudopodia) during GB cell migration. We also observed the expression of known mediators promoting tissue invasion upon RLN2 treatment. We identified PGRMC1, a candidate protein from 2D LC-MS/MS as a novel relaxin target protein in RXFP1-expressing brain tumor cells. RLN2 treatment also caused an increase in cathepsin (cath)-B and -L and enhanced production of as the small Rho-GTPases Rac1 and Cdc42 in GB cells. Collectively, these findings indicate that RXFP1-induced cell migration is mediated by the upregulation and intracellular actions of Rac1, Cdc42 and by cath-B and cath–L who serve as matrix modulating factors to facilitate brain tumor cells migration.
    [Show full text]
  • Altered Expression of RXFP1 Receptor Contributes to the Inefficacy of Relaxin-Based Anti-Fibrotic Treatments in Systemic Sclerosis C
    Altered expression of RXFP1 receptor contributes to the inefficacy of relaxin-based anti-fibrotic treatments in systemic sclerosis C. Corallo1, A.M. Pinto2, A. Renieri2, S. Cheleschi3, A. Fioravanti3, M. Cutolo4, S. Soldano4, R. Nuti1, N. Giordano1 1Scleroderma Unit, Department of ABSTRACT DcSSc-affected fibroblasts only, but not Medicine, Surgery and Neurosciences, Objective. Relaxin is a potent anti-fi- in LcSSc-unaffected and healthy ones. University of Siena; brotic hormone that has been tested to Conclusion. The absence/altered ex- 2Medical Genetics, Department of Medical ameliorate fibrosis in systemic sclerosis pression of relaxin receptor RXFP1 in Biotechnologies, University of Siena; 3Rheumatology Unit, Department of (SSc), but with controversial results. the affected fibroblasts of SSc patients Medicine, Surgery and Neurosciences, The aim of the study is to sequence re- could explain the inefficacy of relaxin- University of Siena; laxin receptor gene RXFP1 and to as- based anti-fibrotic treatments in the 4Research Laboratory and Academic sess its mRNA expression and protein disease. Division of Clinical Rheumatology, levels in the skin of SSc patients and Department of Internal Medicine, healthy subjects. Introduction University of Genova, Italy. Methods. Fibroblasts were isolated Systemic sclerosis (scleroderma, SSc) Claudio Corallo, PhD from unaffected/affected skin samples of is a rare, heterogeneous disease with a Anna Maria Pinto, MD, PhD (n=16) limited-cutaneous-SSc-(LcSSc) high associated mortality, characterised Alessandra Renieri, MD, PhD Sara Cheleschi, PhD and from affected ones of (n=4) diffuse- by progressive fibrosis of the skin and Antonella Fioravanti, MD cutaneous-SSc-(DcSSc) patients. Fibro- internal organs such as lungs, heart, Maurizio Cutolo, MD blasts from healthy subjects were used kidneys and gastrointestinal tract, cou- Stefano Soldano, PhD as controls.
    [Show full text]
  • Distribution, Physiology and Pharmacology of Relaxin-3/RXFP3 Systems in Brain
    British Journal of British Journal of Pharmacology (2017) 174 1034–1048 1034 BJP Pharmacology Themed Section: Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors REVIEW ARTICLE Distribution, physiology and pharmacology of relaxin-3/RXFP3 systems in brain Correspondence Andrew L. Gundlach, The Florey Institute of Neuroscience and Mental Health, 30 Royal Parade, Parkville, Victoria 3052, Australia. E-mail: andrew.gundlach@florey.edu.au Received 25 July 2016; Revised 12 October 2016; Accepted 17 October 2016 Sherie Ma1,2,CraigMSmith1,2,3,AnnaBlasiak4 and Andrew L Gundlach1,2,5 1The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia, 2Florey Department of Neuroscience and Mental Health, The University of Melbourne, Victoria Australia, 3School of Medicine, Deakin University, Geelong, Victoria, Australia, 4Department of Neurophysiology and Chronobiology, Institute of Zoology, Jagiellonian University, Krakow, Poland, and 5Department of Anatomy and Neuroscience, The University of Melbourne, Victoria, Australia Relaxin-3 is a member of a superfamily of structurally-related peptides that includes relaxin and insulin-like peptide hormones. Soon after the discovery of the relaxin-3 gene, relaxin-3 was identified as an abundant neuropeptide in brain with a distinctive topographical distribution within a small number of GABAergic neuron populations that is well conserved across species. Relaxin- 3 is thought to exert its biological actions through a single class-A GPCR – relaxin-family peptide receptor 3 (RXFP3). Class-A comprises GPCRs for relaxin-3 and insulin-like peptide-5 and other peptides such as orexin and the monoamine transmitters. The RXFP3 receptor is selectively activated by relaxin-3, whereas insulin-like peptide-5 is the cognate ligand for the related RXFP4 receptor.
    [Show full text]
  • Relaxin Receptor Antagonist AT-001 Synergizes with Docetaxel in Androgen-Independent Prostate Xenografts
    A Neschadim et al. AT-001 and docetaxel synergize 21:3 459–471 Research in cancer Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts Anton Neschadim, Laura B Pritzker1, Kenneth P H Pritzker1,2,3,4, Donald R Branch5,6,7,8, Alastair J S Summerlee9, John Trachtenberg10,11,12,13 and Joshua D Silvertown Armour Therapeutics, Inc., 124 Orchard View Boulevard, Toronto, Ontario, Canada 1Rna Diagnostics, Inc., 595 Bay Street, Suite 1204, Toronto, Ontario, Canada Departments of 2Laboratory Medicine and Pathobiology, and 3Surgery, University of Toronto, Toronto, Ontario, Canada 4Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada Departments of 5Medicine and 6Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada 7Centre for Innovation, Canadian Blood Services, Toronto, Ontario, Canada 8Division of Advanced Diagnostics – Infection and Immunity, Toronto General Research Institute (TGRI), Correspondence University Health Network, Toronto, Ontario, Canada should be addressed 9Department of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada to J D Silvertown 10Departments of Surgery and Medical Imaging, University of Toronto, Toronto, Ontario, Canada Email 11Division of Urology, Department of Surgical Oncology, 12Prostate Centre, Princess Margaret Hospital, and josh@armourtherapeutics. 13Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada com Endocrine-Related Cancer Abstract Androgen hormones and the androgen receptor (AR) pathway are the main targets of Key Words anti-hormonal therapies for prostate cancer. However, resistance inevitably develops to " prostate cancer treatments aimedattheAR pathway resulting in androgen-independent or hormone-refractory " anti-hormone therapy prostate cancer (HRPC). Therefore, there is a significant unmet need for new, non-androgen " angiogenesis anti-hormonal strategies for the management of prostate cancer.
    [Show full text]
  • Relaxin-3/RXFP3 Networks: an Emerging Target for the Treatment of Depression and Other Neuropsychiatric Diseases?
    Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases? Citation: Smith, Craig M., Walker, Andrew W., Hosken, Ihaia T., Chua, Berenice E., Zhang, Cary, Haidar, Mouna and Gundlach, Andrew L. 2014, Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?, Frontiers in pharmacology, vol. 5, Article 46, pp. 1- 17. DOI: 10.3389/fphar.2014.00046 © 2014, The Authors Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence Downloaded from DRO: http://hdl.handle.net/10536/DRO/DU:30093783 REVIEW ARTICLE published: 21 March 2014 doi: 10.3389/fphar.2014.00046 Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases? Craig M. Smith1,2 *, Andrew W. Walker 1,2 , IhaiaT. Hosken1,2 , Berenice E. Chua1, Cary Zhang1,2 , Mouna Haidar 1,2 and Andrew L. Gundlach1,2,3 * 1 Peptide Neurobiology Laboratory, Neuropeptides Division, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia 2 Florey Department of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia 3 Department of Anatomy and Neuroscience, The University of Melbourne, VIC, Australia Edited by: Animal and clinical studies of gene-environment interactions have helped elucidate the Laurence Lanfumey, Institut National mechanisms involved in the pathophysiology of several mental illnesses including anxiety, de la Santé et de la Recherche Médicale, France depression, and schizophrenia; and have led to the discovery of improved treatments. The study of neuropeptides and their receptors is a parallel frontier of neuropsychopharma- Reviewed by: Sara Morley-Fletcher, Centre National cology research and has revealed the involvement of several peptide systems in mental de la Recherche illnesses and identified novel targets for their treatment.
    [Show full text]
  • The Effect of Estrogen on Tendon and Ligament Metabolism and Function
    Journal of Steroid Biochemistry and Molecular Biology 172 (2017) 106–116 Contents lists available at ScienceDirect Journal of Steroid Biochemistry and Molecular Biology journal homepage: www.elsevier.com/locate/jsbmb Review The effect of estrogen on tendon and ligament metabolism and function MARK ⁎ D.R. Leblanca, M. Schneiderb, P. Angeleb, G. Vollmerc, D. Dochevab,d, a Experimental Surgery and Regenerative Medicine, Department of Surgery, Ludwig-Maximilians-University Munich, Germany b Experimental Trauma Surgery, Department of Trauma Surgery, University Regensburg Medical Centre, Regensburg, Germany c Molecular Cell Physiology and Endocrinology, Institute of Zoology, Technical University, Dresden, Germany d Department of Medical Biology, Medical University-Plodiv, Plodiv, Bulgaria ARTICLE INFO ABSTRACT Keywords: Tendons and ligaments are crucial structures inside the musculoskeletal system. Still many issues in the treat- Estrogen ment of tendon diseases and injuries have yet not been resolved sufficiently. In particular, the role of estrogen- Musculoskeletal tissues like compound (ELC) in tendon biology has received until now little attention in modern research, despite ELC Tendons and ligaments being a well-studied and important factor in the physiology of other parts of the musculoskeletal system. In this Tendon cells review we attempt to summarize the available information on this topic and to determine many open questions in this field. 1. Introduction increase in the risk of cardio-vascular events, breast- and endometrial- cancer as well as thromboembolic events [7]. SERMs are a class of drugs For a long time estrogens have been known as a regulating factor of defined by their ability to target the same receptors as estrogen while the metabolism in many connective tissues, like bone [1], muscle [2] differing in their preference towards the various receptor-subtypes and and cartilage [3].
    [Show full text]
  • Session 7. Protein Functions in Cellular Signaling Lectures L7.1 L7.2
    Session 7. Protein Functions in Cellular Signaling Lectures L7.2 L7.1 Neutrophil extracellular traps (NETs) in autoinflammatory responses Molecular basis of macrophage Joanna Cichy activation by lipopolysaccharide Jagiellonian University, Faculty of Biochemistry, Biophysics & Katarzyna Kwiatkowska Biotechnology, Department of Immunology, Kraków, Poland e-mail: Joanna Cichy <[email protected]> Nnencki Institute of Experimental Biology, Department of Cell Biology, Warsaw, Poland e-mail: Katarzyna Kwiatkowska <[email protected]> Neutrophils also referred to as polymorphonuclear leuko- cytes (PMNs) form a part of the front line of host defense Lipopolysaccharide (LPS, endotoxin) is a component of against pathogens and are key component of tissue infil- the outer membrane of Gram-negative bacteria. LPS is an trates in autoinflammatory diseases such as systemic lupus archetypical pathogen-associated molecular pattern which erythematosus (SLE) and psoriasis. Activated neutrophils activates of one of Toll-like receptors (TLR), TLR4, of im- can eliminate microbes by the formation of neutrophil ex- mune cells. Upon infection it strongly stimulates production tracellular traps (NETs), extracellular decondensed chro- of pro-inflammatory mediators by macrophages. Excessive matin networks decorated with microbicidal agents. NETs host responses to LPS can lead to a systemic inflammatory were first reported to limit the growth and spread of mi- condition named septic shock. A relatively high incidence croorganisms through mechanically trapping pathogens and mortality of the disease drive studies on molecular and facilitating interaction of anti-microbial agents that are mechanisms of activation of cells by LPS. displayed on NETs with bacteria or fungi. More recently, In a typical scenario, activation of TLR4 is a multistep NETs were associated with tissue damage and autoinflam- process which begins in blood serum with binding of LPS matory diseases.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0237454 A1 Schutzer (43) Pub
    US 2013 0237454A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0237454 A1 Schutzer (43) Pub. Date: Sep. 12, 2013 (54) DIAGNOSTIC MARKERS FOR Publication Classification NEUROPSYCHATRC DISEASE (51) Int. Cl. (76) Inventor: Steven E. Schutzer, Water Mill, NY GOIN33/68 (2006.01) (US) (52) U.S. Cl. CPC .................................. G0IN33/6896 (2013.01) (21) Appl. No.: 13/697,417 USPC ............................................................ SO6/12 (22) PCT Filed: May 12, 2011 (57) ABSTRACT Biomarkers for the diagnosis of neuropsychiatric diseases are (86). PCT No.: PCT/US11?0O843 presented herein. In particular embodiments, biomarkers are S371 (c)(1), identified that are useful for diagnosing multiple Sclerosis, (2), (4) Date: May 23, 2013 chronic fatigue syndrome, or Neurologic Lyme disease. Also encompassed is a method for diagnosing a patient with a Related U.S. Application Data neuropsychiatric disease. Such as multiple Sclerosis, chronic AV fatigue syndrome, or Neurologic Lyme disease, by analyzing (60) Provisional application No. 61/395,354, filed on May biological samples isolated from the patient or the patient as 12, 2010. a whole to assess levels of the biomarkers described herein. -N- 1895 72% 63 735 8% 92% Patent Application Publication Sep. 12, 2013 US 2013/0237454 A1 Figure l US 2013/0237454 A1 Sep. 12, 2013 DAGNOSTIC MARKERS FOR tiple Sclerosis is more common in women than men and NEUROPSYCHATRC DISEASE generally begins between ages 20 and 40, but can develop at any age. Multiple Sclerosis is generally viewed as an autoim FIELD OF THE INVENTION mune syndrome directed against unidentified central nervous 0001. The present invention relates to identifying biologic tissue antigens.
    [Show full text]